Safety and Immunogenicity of 2-dose Inactivated COVID-19 Vaccine in Kidney Transplant Recipients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

300 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-08-01

Study Completion Date

2021-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has a major impact on transplant recipients, with mortality rates up to 20%. However, immunocompromised individuals have been excluded from studies of SARS-CoV-2 vaccines. In such patients, the immune response to vaccination may be blunted. To better understand the immunogenicity of SARS-CoV-2 vaccines in transplant recipients, we quantified the humoral response to SARS-CoV-2 vaccine in kidney transplant recipients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Effectiveness of COVID-19 Vaccine in Kidney Transplant Recipients

NCT05156086

COVID-19 Vaccination Renal Transplant

UNKNOWN

Evaluate the Impact, Safety, Tolerability and Immunogenicity of the Coronavac Vaccine in Kidney Transplant Recipients

NCT04801667

SARS-CoV Infection Coronavirus Infection Vaccine Adverse Reaction

UNKNOWN PHASE4

Immunological Follow-up After SARS CoV2 Vaccination in Kidney Transplant Recipients

NCT04757883

Kidney Transplant Recipients

TERMINATED

Covid-19 Vaccine Response in Heart Transplant Recipients

NCT05268679

Heart Transplantation COVID-19 Virus Infection COVID-19 Vaccine

COMPLETED

Vaccination Against COVID-19 in Chronic Kidney Disease

NCT04743947

Chronic Kidney Disease Stage 5 on Dialysis Chronic Kidney Disease Stage 5 With Transplant Vaccine Response Impaired

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Kidney Transplantation SARS-CoV-2 Acute Respiratory Disease Vaccine

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

kidney transplant recipients

kidney transplant recipients receiving inactivated SARS-CoV-2 vaccine

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Receiving kidney transplantation in West China Hospital, Sichuan University

Exclusion Criteria

1\) History of rejection or infection over the previous 3 months; 2) receiving kidney transplantation \>3 months; 3) Combined with HBV/HVC/HIV infection in the donor or recipient; 4) Malignancy history in the donor and recipient; 5) organ transplant history in the recipient.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No